MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 204640 | Name: Infigratinib free base
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Infigratinib, also known as, BGJ398 or NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib was approved in 2021 to treat adults with cholangiocarcinoma whose disease meets certain criteria.

Chemical Structure

Infigratinib free base
Infigratinib free base
CAS#872511-34-7 (free base)

Theoretical Analysis

MedKoo Cat#: 204640

Name: Infigratinib free base

CAS#: 872511-34-7 (free base)

Chemical Formula: C26H31Cl2N7O3

Exact Mass: 559.1865

Molecular Weight: 560.47

Elemental Analysis: C, 55.72; H, 5.57; Cl, 12.65; N, 17.49; O, 8.56

Price and Availability

Size Price Availability Quantity
25mg USD 90.00 Ready to ship
50mg USD 150.00 Ready to ship
100mg USD 250.00 Ready to ship
200mg USD 450.00 Ready to ship
500mg USD 950.00 Ready to ship
1g USD 1,650.00 Ready to ship
2g USD 2,950.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
872511-34-7 (free base) 1310746-10-1 (phosphate) 1310746-11-2 (monohydrate) 1310746-12-3 (mesylate)
Synonym
NVPBGJ398; NVPBGJ 398; NVPBGJ-398; BGJ398; BGJ-398; BG J398; Infigratinib.
IUPAC/Chemical Name
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea.
InChi Key
QADPYRIHXKWUSV-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
SMILES Code
O=C(NC1=C(Cl)C(OC)=CC(OC)=C1Cl)N(C2=NC=NC(NC3=CC=C(N4CCN(CC)CC4)C=C3)=C2)C
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
BGJ398 is a potent, selective and orally active pan-FGFR inhibitor, with IC50s of 0.9, 1.4, 1.0 and 60 nM for FGFR1, 2, 3 and 4, respectively. CAS#872511-34-7 ( BGJ-398 free base); 1310746-11-2 (BGJ-398 monohydrate); 1310746-10-1 (BGJ-398 phosphate salt)    
Biological target:
Infigratinib (BGJ-398; NVP-BGJ398) is an inhibitor of the FGFR family with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
In vitro activity:
Infigratinib inhibits FGF-induced activation of the FGFR signaling pathway and cell cycle progression. Pretreatment of HCC01-0909 cells with 1.0 µM Infigratinib for 18 hours abolished FGF-2-, FGF-1-, and FGF-19- stimulated phosphorylation of Fibroblast Growth Factor Receptor Substrate 2 alpha (FRS2-α) and extracellular signal-regulated kinase (ERK)1/2 (Fig. 1C). Infigratinib had no effect on HGF-induced phosphorylation of ERK1/2, suggesting that the inhibitory effect of infigratinib was specific to the FGF/FGFR signaling pathway. Infigratinib caused a significant increase in the percentage of cells in the G1 and sub-G1 phases with a concomitant reduction in the percentage of cells in the G2/M and S phases (Fig. 1D), suggesting that infigratinib causes G1 cell cycle arrest. Reference: Hepatology. 2019 Mar;69(3):943-958. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635738/
In vivo activity:
Daily treatment of HCC06-0606 tumor-bearing mice with 10, 20, and 30 mg/kg infigratinib for 14 days led to approximately 65%, 96%, and 98% reductions in tumor burden, respectively (Fig. 1E). Daily treatment of mice with infigratinib resulted in significant elevation in alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase (AST) and a significant decrease in serum creatinine (Supporting Fig. S2). Infigratinib potently inhibited p-FRS2-α and p-ERK1/2 (Figure 1F), and the inhibition of these biomarkers occurred within 2 hours after a single oral dose of 20 mg/kg infigratinib, was maintained for approximately 10 hours, and returned to baseline by 12 hours after treatment (Fig. 2A). Reference: Hepatology. 2019 Mar;69(3):943-958. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635738/
Solvent mg/mL mM
Solubility
DMSO 6.7 11.90
Water 0.1 0.09
DMF 5.0 8.92
DMF:PBS (pH 7.2) (1:30) 0.0 0.05
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 560.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Huynh H, Lee LY, Goh KY, Ong R, Hao HX, Huang A, Wang Y, Graus Porta D, Chow P, Chung A. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 2019 Mar;69(3):943-958. doi: 10.1002/hep.30481. PMID: 30575985; PMCID: PMC6635738.
In vitro protocol:
1. Huynh H, Lee LY, Goh KY, Ong R, Hao HX, Huang A, Wang Y, Graus Porta D, Chow P, Chung A. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 2019 Mar;69(3):943-958. doi: 10.1002/hep.30481. PMID: 30575985; PMCID: PMC6635738.
In vivo protocol:
1. Huynh H, Lee LY, Goh KY, Ong R, Hao HX, Huang A, Wang Y, Graus Porta D, Chow P, Chung A. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 2019 Mar;69(3):943-958. doi: 10.1002/hep.30481. PMID: 30575985; PMCID: PMC6635738.
1: Tran A, Koh TS, Prawira A, Ho RZW, Le TBU, Vu TC, Hartano S, Teo XQ, Chen WC, Lee P, Thng CH, Huynh H. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High- FGFR-Expressing Hepatocellular Carcinoma Xenografts. Mol Imaging Biol. 2020 Sep 9. doi: 10.1007/s11307-020-01531-7. Epub ahead of print. PMID: 32909245. 2: Magone MT, Hartley IR, Fitzgibbon E, Bishop R, Arango M, Moran S, Vold R, Rivero JD, Pozo K, Streit J, Roszko KL, Collins MT, Gafni RI. Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor. Ophthalmology. 2020 Sep 1:S0161-6420(20)30844-7. doi: 10.1016/j.ophtha.2020.08.026. Epub ahead of print. PMID: 32888946. 3: Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal SK. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol. 2020 Aug 23:S0302-2838(20)30616-3. doi: 10.1016/j.eururo.2020.08.002. Epub ahead of print. PMID: 32847703. 4: Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Jun 25. doi: 10.2217/fon-2020-0299. Epub ahead of print. PMID: 32580579. 5: Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer. 2020 Jun 1;126(11):2597-2606. doi: 10.1002/cncr.32806. Epub 2020 Mar 24. PMID: 32208524; PMCID: PMC7515773. 6: Felix NS, de Mendonça L, Braga CL, da Silva JS, Samary CDS, Vieira JB, Cruz F, Rocha NN, Zapata-Sudo G, Rocco PRM, Silva PL. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. Br J Pharmacol. 2019 Dec;176(23):4462-4473. doi: 10.1111/bph.14807. Epub 2019 Dec 5. PMID: 31351013; PMCID: PMC6932937. 7: Huynh H, Lee LY, Goh KY, Ong R, Hao HX, Huang A, Wang Y, Graus Porta D, Chow P, Chung A. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 2019 Mar;69(3):943-958. doi: 10.1002/hep.30481. PMID: 30575985; PMCID: PMC6635738.